Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study.

BMC cancer·2026

Same author

Human rights violations reporting dataset.

Data in brief·2026

Same author

Clinical Significance of Microembolic Signal Detection in Acute Ischemic Stroke: Insights Into Ongoing Cerebral Embolization and Occult Etiologies.

European journal of neurology·2026

Same author

Effect of Camelina sativa seeds on rumen microbiota and fermentation in dairy sheep.

Journal of animal science·2026

Same author

Real-World Neoadjuvant Systemic Therapy Utilization and Treatment Patterns in Patients with Early-Stage or Locally Advanced Triple-Negative Breast Cancer in Greece-The TRINITY Study.

Cancers·2025

Same author

Understanding exceptional response: The role of MINDY1 SNP in CDK4/6 inhibitor therapy for ER<sup>+</sup>, HER2<sup>-</sup> advanced breast cancer.

HGG advances·2025

Search research articles

Related Experiment Videos

Can cetuximab affect paraneoplastic myopathy?

Eleni Galani¹, Anastasios Bonakis, Christos Christodoulou

¹Second Oncology Department, Metropolitan Hospital, Athens, Greece.

Journal of Neuro-Oncology

|January 23, 2009

Summary

Cetuximab may help treat paraneoplastic necrotizing myopathy in metastatic colon cancer patients. This rare condition possibly responded to cetuximab, even when the cancer itself did not improve.

Related Experiment Videos

Area of Science:

Oncology
Neurology
Immunology

Background:

Metastatic colon cancer (mCC) treatment often involves chemotherapy combined with targeted therapies like cetuximab.
Paraneoplastic syndromes, including necrotizing myopathy, can complicate cancer treatment.
The efficacy of cetuximab in paraneoplastic syndromes is not well-established.

Observation:

A patient with metastatic colon cancer developed paraneoplastic necrotizing myopathy.
The patient received cetuximab concurrently with chemotherapy for their cancer.
Muscle inflammation and weakness were the primary symptoms of the myopathy.

Findings:

The patient's necrotizing myopathy showed possible improvement with cetuximab treatment.
This response occurred despite the underlying metastatic colon cancer not showing improvement.
The findings suggest a potential immunomodulatory or direct effect of cetuximab on the paraneoplastic process.

Implications:

Cetuximab may represent a therapeutic option for paraneoplastic necrotizing myopathy in colon cancer.
Further research is warranted to confirm cetuximab's role in managing paraneoplastic syndromes.
Understanding this interaction could lead to novel treatment strategies for cancer-associated neurological complications.